Lead optimization of new antibacterials/antimalarials that target ACP synthase

该项目专注于生产“广谱”的新型抗生素药物，以治疗所有类型的耐药细菌感染，以及潜在的结核病和疟疾。耐药性是一个日益严重的问题，这使得目前的抗生素比以前效果差得多。这在葡萄球菌耐药菌株中尤其令人担忧。金黄色葡萄球菌(“超级细菌”MRSA)；由大肠杆菌引起的革兰氏阴性感染；由结核分枝杆菌菌株引起的所谓“XDR”结核病；以及疟疾，其病原体是Pl。恶性疟原虫。所有这些不同的疾病都可以被同一种药物靶向，只要它们的作用机制都存在。这项提议使用在以前的工作中开发的能够杀死MRSA的新型化合物，作为制造这种广谱抗生素的起点。我们的化合物针对ACP

This project focuses on producing new antibiotic drugs that are "broad-spectrum" to treat all types of drug-resistant bacterial infections as well as, potentially, tuberculosis and malaria. Drug resistance is a growing problem that has made current antibiotics much less effective than before. This is of special concern in resistant strains of Staph. aureus (the "superbug" MRSA); Gram-negative infections caused by E. coli; so-called "XDR" tuberculosis caused by strains of Mycobacterium tuberculosis; and malaria, the causative agent of which is Pl. falciparum. All of these diverse diseases can be targeted by the same drug, provided the mechanism of action is present in all of them. This proposal uses novel compounds that kill MRSA, developed in previous work, as a starting point for making such broad-spectrum antibiotics. Our compounds target ACP